Clinical trials: Large Bowel Cancer
Liver Metastases, Colorectal Carcinoma
An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
- Trial name
- NCT03029988
- Testing
- Tilmanocept (Technetium Tc 99m tilmanocept Injection), SPECT/CT Imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Navidea Biopharmaceuticals
Neoplasms, Colorectal Cancer
Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
This study will evaluate the safety, tolerability and preliminary efficacy of MK-8353 when administered in combination with pembrolizumab (MK-3475).
- Trial name
- NCT02972034
- Testing
- MK-8353, Pembrolizumab
- Where
- 3 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
Regorafenib in Metastatic Colorectal Cancer
The purpose of the study is to measure high grade (3-5) toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer.
- Trial name
- NCT02466009
- Testing
- Regorafenib
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Rochester
Colorectal Cancer
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
This research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer. The name of the study intervention involved in this study is: Low Dose Aspirin
- Trial name
- NCT05056896
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
This observational study will evaluate the safety and efficacy of Bevacizumab in combination with 5-Fluorouracil based chemotherapy as first-line and second-line therapy in Chinese participants with metastatic colorectal cancer.
- Trial name
- NCT01319877
- Where
- 24 sites in China
- Volunteers
- 609 people
- Sponsor
- Hoffmann-La Roche
Thyroid Cancer, Colon Cancer
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred…
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03127098
- Testing
- ETBX-011, ALT-803
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NantCell, Inc.
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
This phase II trial studies how well v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor MK2206 works in treating patients with previously treated colon or rectal cancer that has spread from the primary site to other…
- Conditions
- Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
- Trial name
- NCT01802320
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Secondary Malignant Neoplasm of Liver, Colorectal Neoplasms
Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study
The purpose of the study is to compare outcomes of laparoscopic versus open liver resection for colorectal metastases in a prospective and randomized study.
- Trial name
- Oslo-CoMet (NCT01516710)
- Testing
- Open liver resection, Laparoscopic liver resection
- Where
- Norway
- Volunteers
- 280 people
- Sponsor
- Oslo University Hospital
Colorectal Cancer
Pilot Study of GVAX in Colorectal Cancer Cells
This study is a Pilot clinical trial. Pilot clinical trials test the safety of an investigational combination of drugs. Pilot studies provide information on what effects, both good and bad, the Investigational agent might have on…
- Trial name
- NCT01952730
- Testing
- GVAX
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
This 2 arm study will compare the safety and efficacy of oral Xeloda, or 5-fluorouracil in combination with leucovorin, in patients who have undergone surgery for colon cancer.
- Trial name
- NCT00009737
- Testing
- 5-Fluorouracil, Leucovorin, Capecitabine [Xeloda]
- Where
- 133 sites in United States, Argentina and 12 more
- Volunteers
- 1,987 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Lung Cancer
Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.
This randomized control trial will investigate the ability of an effective stress management psychoeducation program for employed caregivers to mitigate psychological distress and pathophysiology in spousal or partnered…
- Conditions
- Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
- Trial name
- eCare (NCT04739696)
- Testing
- PEPRR, Pep-Pal
- Where
- United States
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Metastatic Colorectal Cancer
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
This is a Phase 1b/2a study investigating the safety and efficacy of Sym004, an investigational medicinal product (IMP), in combination with FOLFIRI (chemotherapy) when administered every second week (Q2W).
- Trial name
- NCT02568046
- Testing
- Sym004, FOLFIRI
- Where
- 8 sites in United States, Spain
- Volunteers
- 10 people
- Sponsor
- Symphogen A/S
Colorectal Adenoma, Colorectal Carcinoma
Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
The purpose of this study is to assess how effective celecoxib is in limiting production of a hormone, prostaglandin, in the subject's body.
- Trial name
- UAB0040 (NCT00582660)
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Colorectal Cancer, Colorectal Carcinoma
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
This study is a randomized multi-center trial that will assess the effect of adding Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard chemotherapy regimen of FOLFOX as first line therapy…
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
- Trial name
- SIRFLOX (NCT00724503)
- Testing
- SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX)
- Where
- 111 sites in United States, Australia and 9 more
- Volunteers
- 530 people
- Sponsor
- Sirtex Medical
Colorectal Cancer, Metastatic Colorectal Cancer
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
This phase I/II trial studies the best dose and side effects of glutaminase inhibitor CB-839 and how well it works with panitumumab and irinotecan hydrochloride (phase I only) in treating patients with RAS wildtype colorectal…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, RAS Wild Type Colorectal Cancer, Refractory Colorectal Cancer
- Trial name
- NCT03263429
- Testing
- Glutaminase Inhibitor CB-839, Panitumumab, Irinotecan Hydrochloride (phase I only)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Colon Adenocarcinoma, ERBB2 Gene Amplification
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it…
- Conditions
- Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma
- Trial name
- NCT03365882
- Testing
- Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- SWOG Cancer Research Network
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has…
- Conditions
- Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
- Trial name
- CheckMate142 (NCT02060188)
- Testing
- Ipilimumab, Nivolumab, Cobimetinib
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 385 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and…
- Trial name
- NCT00419159
- Testing
- Everolimus (RAD001)
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
The main purpose of this study is to evaluate the best dose, safety and side effects of ridaforolimus when given with cetuximab for patients with head and neck, lung and colon cancer that has progressed after initial therapy.
- Trial name
- NCT01212627
- Testing
- Ridaforolimus
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Angela Taber MD
Breast Cancer, Prostate Cancer
Survivorship Promotion In Reducing IGF-1 Trial
This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus…
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
- Trial name
- SPIRIT (NCT02431676)
- Testing
- Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins